Xeris Biopharma to Report Fourth Quarter and Full Year 2021 Financial Results on March 10, 2022
March 04 2022 - 7:00AM
Business Wire
Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a
biopharmaceutical company developing and commercializing unique
therapies for patient populations in endocrinology, neurology, and
gastroenterology, today announced that the Company will release its
fourth quarter and full year 2021 financial results before the open
of the U.S. financial markets on Thursday, March 10, 2022.
Management will host a conference call and webcast at 8:30 a.m.
Eastern Time that day to discuss the Company’s financial and
operational results.
To pre-register for the conference call please use this link:
https://www.incommglobalevents.com/registration/q4inc/9809/xeris-biopharma-fourth-quarter-2021-financial-results-conference-call-and-webcast/.
After registering, a confirmation email will be sent, including
dial-in details and a unique code for entry. The Company recommends
registering a minimum of ten minutes prior to the start of the
call. Following the conference call, a replay will be available
until Thursday, March 24, 2022, at US:1 929 458 6194, US Toll Free:
1 866 813 9403, UK: 0204 525 0658, Canada: 1 226 828 7578, or all
other locations: +44 204 525 0658 Access Code: 872042. In addition,
a live audio of the conference call will be available as a webcast.
To join the webcast, please visit “Events” on investor relations
page of the Company’s website at www.xerispharma.com.
About Xeris Biopharma Holdings, Inc.
Xeris (Nasdaq: XERS) is a biopharmaceutical company developing
and commercializing unique therapies for patient populations in
endocrinology, neurology, and gastroenterology. Xeris has three
commercially available products; Gvoke®, a ready-to-use liquid
glucagon for the treatment of severe hypoglycemia, Keveyis®, the
first and only FDA-approved therapy for primary periodic paralysis,
and Recorlev® for the treatment of endogenous Cushing’s syndrome.
Xeris also has a robust pipeline of development programs to extend
the current marketed products into important new indications and
uses and bring new products forward using its proprietary
formulation technology platforms, XeriSol™ and XeriJect™,
supporting long-term product development and commercial
success.
Xeris Biopharma Holdings is headquartered in Chicago, IL. For
more information, visit www.xerispharma.com, or follow us on
Twitter, LinkedIn or Instagram.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220304005074/en/
Investor Contact Allison Wey Senior Vice President,
Investor Relations and Corporate Communications
awey@xerispharma.com 312-736-1237
Xeris Biopharma (NASDAQ:XERS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Xeris Biopharma (NASDAQ:XERS)
Historical Stock Chart
From Jul 2023 to Jul 2024